Axsome Therapeutics Reports 52% Revenue Growth Driven by Auvelity Sales
Axsome Therapeutics (AXSM) reported strong third-quarter 2026 financial results, highlighted by a 52% year-over-year revenue increase to $260 million. The growth was primarily driven by its flagship treatment, Auvelity, which generated $208 million in the quarter—a 53% increase fueled by rising adoption among primary care prescribers for major depressive disorder and Alzheimer's disease agitation. Beyond current sales, the company is leveraging a robust late-stage neuroscience pipeline consisting of 10 clinical programs targeting conditions like narcolepsy and fibromyalgia. With $314 million in cash on hand, management expects to fund operations through to cash flow positivity without needing dilutive financing. The company's strategic focus remains on expanding primary care coverage and navigating upcoming clinical readouts scheduled through 2027.
Tickers: $AXSM
Topics: earnings report neuroscience pharmaceuticals revenue growth
Read the full article at Motley Fool
Part of the story UroGen Pharma Reports Strong Revenue Growth Driven by Zosturi Sales (7 articles)